The most recent (Spring 2023) international recommendations for treatment of PMR and GCA are suggesting a much more patient-centred approach with shared decision making between the clinician and a well informed patient at its heart, rather than basing treatment on a rigidly imposed taper schedule.
As is already the case for many other rheumatological conditions, the target is for the patient to be symptom-free and the disease controlled safely on the lowest possible steroid dose, accepting that for many this will not be zero. You can read the full paper on our medical information page.
